Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1496-502. doi: 10.1016/j.ijrobp.2009.12.071. Epub 2010 Oct 29.
To review institutional outcomes for patients treated with external-beam radiotherapy (EBRT) for orbital pseudotumor.
This is a single-institution retrospective review of 20 orbits in 16 patients diagnosed with orbital pseudotumor that received EBRT at the University of Oklahoma, Department of Radiation Oncology. Treated patients had a median follow-up of 16.5 months.
Fifteen patients (93.7%) were initially treated with corticosteroids. Eight had recurrence after steroid cessation, six were unable to taper corticosteroids completely or partially, and one experienced progression of symptoms despite corticosteroid therapy. Fourteen patients (87.5%) initially responded to radiotherapy indicated by clinical improvement of preradiation symptoms and/or tapering of corticosteroid dose. Mean EBRT dose was 20 Gy (range, 14-30 Gy). Thirteen patients (81.2%) continued to improve after radiation therapy. Patient outcomes were complete cessation of corticosteroid therapy in nine patients (56.3%) and reduced corticosteroid dose in four patients (25%). Radiotherapy did not achieve long-term control for three patients (18.7%), who still required preradiation corticosteroid dosages. Three patients received retreatment(s) of four orbits, of which two patients achieved long-term symptom control without corticosteroid dependence. One patient received retreatment to an orbit three times, achieving long-term control without corticosteroid dependence. No significant late effects have been observed in retreated patients.
Radiotherapy is an effective treatment for acute symptomatic improvement and long-term control of orbital pseudotumor. Orbital retreatment can be of clinical benefit, without apparent increase in morbidity, when initial irradiation fails to achieve complete response.
回顾接受外照射放射治疗(EBRT)治疗眼眶假性肿瘤患者的机构治疗结果。
这是俄克拉荷马大学放射肿瘤学系对 16 名被诊断为眼眶假性肿瘤并接受 EBRT 治疗的 20 只眼眶的单机构回顾性研究。接受治疗的患者中位随访时间为 16.5 个月。
15 名患者(93.7%)最初接受皮质类固醇治疗。8 名患者在类固醇停药后复发,6 名患者无法完全或部分减少皮质类固醇剂量,1 名患者尽管接受皮质类固醇治疗但症状仍进展。14 名患者(87.5%)最初对放射治疗有反应,表现为放疗前症状改善和/或皮质类固醇剂量减少。平均 EBRT 剂量为 20 Gy(范围 14-30 Gy)。13 名患者(81.2%)在放射治疗后继续改善。9 名患者(56.3%)完全停止皮质类固醇治疗,4 名患者(25%)皮质类固醇剂量减少。3 名患者(18.7%)的放射治疗未实现长期控制,仍需放疗前的皮质类固醇剂量。3 名患者接受了 4 只眼眶的再治疗,其中 2 名患者在不依赖皮质类固醇的情况下实现了长期症状控制。1 名患者对 1 只眼眶进行了 3 次再治疗,在不依赖皮质类固醇的情况下实现了长期控制。接受再治疗的患者没有观察到明显的迟发性不良反应。
放射治疗是治疗眼眶假性肿瘤急性症状改善和长期控制的有效方法。当初次照射未能达到完全缓解时,眼眶再治疗可以带来临床益处,且不会明显增加发病率。